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Background: Alteplase is the only approved thrombolytic agent for acute ischaemic stroke. The overall benefit
from alteplase is substantial, but some evidence indicates that alteplase also has negative effects on the ischaemic
brain. Tenecteplase may be more effective and less harmfull than alteplase, but large randomised controlled phase
3 trials are lacking. The Norwegian Tenecteplase Stroke Trial (NOR-TEST) aims to compare efficacy and safety of
tenecteplase vs. alteplase.
Methods/Design: NOR-TEST is a multi-centre PROBE (prospective randomised, open-label, blinded endpoint) trial
designed to establish superiority of tenecteplase 0.4 mg/kg (single bolus) as compared with alteplase 0.9 mg/kg
(10% bolus + 90% infusion/60 minutes) for consecutively admitted patients with acute ischaemic stroke eligible for
thrombolytic therapy, i.e. patients a) admitted <4½ hours after symptoms onset; b) admitted <4½ hours after
awakening with stroke symptoms c) receiving bridging therapy before embolectomy.
Randomisation tenecteplase:alteplase is 1:1. The primary study endpoint is favourable functional outcome defined
as modified Rankin Scale 0–1 at 90 days. Secondary study endpoints are: 1) haemorrhagic transformation
(haemorrhagic infarct/haematoma); 2) symptomatic cerebral haemorrhage on CT 24–48 hours; 3) major
neurological improvement at 24 hours; 4) recanalisation at 24–36 hours; 5) death.
Discussion: NOR-TEST may establish a novel approach to acute ischaemic stroke treatment. A positive result
will lead to a more effective, safer and easier treatment for all acute ischaemic stroke pasients.
NOR-TEST is reviewed and approved by the Regional Committee for Medical and Health Research Ethics
(2011/2435), and The Norwegian Medicines Agency (12/01402). NOR-TEST is registered with EudraCT No
2011-005793-33 and in ClinicalTrials.gov (NCT01949948).
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Alteplase is the only approved treatment for acute ischae-
mic stroke within 4½ hours after stroke onset. The overall
benefit from alteplase is substantial, but up to 2/3 of
patients with large artery occlusions may not achieve reca-
nalisation and less than half of the patients treated, have
complete reperfusion by 24 hours [1]. Up to 40% of
thrombolysed stroke patients may therefore remain se-
verely disabled or die [2], leaving substantial room for im-
provement. A growing body of evidence indicates that
alteplase also has negative effects on the ischaemic brain,
including cytotoxicity and increased permeability of the
blood–brain–barrier facilitating cerebral edema [3-6]. An
alternative thrombolytic therapy that might be easier and
safer to administer could lead to wider acceptance and use
of thrombolytic therapy [7]. Tenecteplase may be the drug
of choice [8]. Tenecteplase is a modified tissue plasmino-
gen activator that is more fibrin-specific, more resistant to
plasminogen activator inhibitor (PAI), has a longer half-
life than alteplase and can therefore be administered as an
intravenous bolus [1,7,9].
In animal models of acute ischaemic stroke, tenecteplase
results in more rapid and complete reperfusion, and less
hemorrhagic conversion of experimental infarcts than
equipotent doses of alteplase [10,11].
Several clinical trials of patients with myocardial infarc-
tion have shown that tenecteplase induces more rapid
coronary reperfusion, with similar mortality rates, but sig-
nificantly reduced rate of major bleeds as compared with
alteplase [1,9,12].
In a dose-escalation safety study of tenecteplase, no
symptomatic intracranial haemorrhages (SICH) were
found among 88 ischaemic stroke patients treated with
doses ranging from 0.1 mg/kg to 0.4 mg/kg [9].
A randomised study of tenecteplase (0.4 mg/kg) vs.
standard alteplase in stroke patients (n = 122) with MCA
occlusion and perfusion lesion ≥20% greater than the in-
farct core has shown that tenecteplase (0.4 mg/kg) leads
to faster and more complete MCA 2 h-recanalization, bet-
ter 24 h improvement, and better long-term outcome,
without increased risk of cerebral haemorrhage [13].
A dose-ranging study of tenecteplase for patients with
acute ischemic stroke, using standard clinical selection cri-
teria, showed that a dose of 0.4 mg/kg was associated with
excess SICH, whereas no difference was found between
doses of 0.1 mg/kg and 0.25 mg/kg. Due to SICH and slow
enrollment, the trial was stopped prematurely [7].
In a recently published randomised trial of tenecteplase
0.1 mg/kg (n = 25), tenecteplase 0.25 mg/kg (n = 25) or
alteplase 0.9 mg/kg (n = 25) within a 6 hour time window
and using CT-perfusion (mismatch) and CT-angiography
(visible occlusion) as imaging entry criteria, tenecteplase
was associated with better reperfusion, less SICH and bet-
ter clinical outcome than alteplase [14].Wake-up stroke (WUPS) patients are not eligible for
thrombolytic treatment because the time of onset is not
known. Patients with an acute ischaemic lesion detected
with DW-MRI but not with FLAIR imaging are likely to
be within a time window in which thrombolysis is safe
and effective [15]. Intravenous thrombolysis with alte-
plase seems to be an independent determinant of a bet-
ter outcome in WUPS and associated with a 5-fold odds
of achieving an mRS 0 to 2 at 90 days without increasing
the risk of haemorrhage [16]. The effect of tenecteplase
in WUPS patients has not been studied.
Embolectomy recanalises large artery occlusions more
effectively and rapidly than intravenous alteplase alone.
Intravenous alteplase is routinely administered prior to
endovascular treatment as a “bridging therapy”. There is
no published evidence indicating an increased risk of
combining tenecteplase with endovascular treatment.
Aims
Aim of the Norwegian Tenecteplase Stroke Trial (NOR-
TEST) is to compare efficacy and safety of tenecteplase
0.4 mg/kg (single bolus) vs. alteplase 0.9 mg/kg (10%
bolus + 90% infusion/60 minutes) given a) <4½ hours
after symptom onset, b) <4½ hours after awakening with
stroke symptoms, and c) as bridging therapy before em-
bolectomy <6 hours after symptom onset.
Methods/Design
Study design
NOR-TEST is a multi-centre PROBE (prospective ran-
domised, open-label, blinded endpoint) trial, designed to
establish superiority of tenecteplase as compared with alte-
plase for consecutively admitted patients with acute ischae-
mic stroke treated a) within 4½ hours after the onset of
symptoms, b) within 4½ hours after awakening with symp-
toms, and c) within 6 hours after the onset of symptoms if
eligible for embolectomy. Randomisation tenecteplase:alte-
plase is 1:1. The randomisation procedure uses envelopes
in the thrombolysis-medication box to reduce time delay.
Sample size
Power calculation was based on data from the following
studies: pooled analysis of alteplase trials (n = 463) [17],
SITS-MOST (n = 10.772) [18,19], the Bergen NORSTROKE
2007–2011 (n = 134) [i.e. alteplase in routine practice] and
Parsons 2012 (n = 75) [i.e. tenecteplase RCT] [14].
NOR-TEST aims to detect a 9% higher percentage ex-
cellent outcome with tenecteplase vs. alteplase (r1 = 0.40;
r2 = 0.49; OR 1.44; power 0.8), which requires inclusion
of 954 patients (see Additional file 1). The study was
initiated at Haukeland University Hospital, Bergen, in
September 2012 and at the other centres during 2013
and January 2014. NOR-TEST is expected to be ended
in autumn 2016.
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All patients found eligible for routine thrombolytic therapy
are eligible for NOR-TEST. Inclusion criteria for thrombo-
lytic therapy are defined as follows:
 Age 18 years or older.
 Ischaemic stroke with measurable deficit on
National Institute of Health Stroke Scale (NIHSS).
 All ischaemic stroke sub-types and vascular distributions.
A visible arterial occlusion is not required.
 Treatment within 4½ hours of stroke onset.
 Informed written consent signed by the patient, or
verbal consent from the patient as witnessed by a
non-participating health care person, or consent by
the signature of the patient's family must be
provided before treatment. Patients for whom no
informed consent can be obtained will not be
included in the study, but will be treated according
to standard guidelines.
Specific sub-set inclusion criteria
 Wake-Up Stroke: Treatment within 4½ hours after
awakening based on FLAIR-DWI mismatch on
MRI [15].
 Embolectomy: Occlusion of cerebral intra-arterial
vessel technically accessible for endovascular
embolectomy <4½ hours after stroke onset or
awakening; or <6 hours if based on penumbra
assessment (as defined by local treatment protocols).
Exclusion criteria for thrombolytic therapy are defined
as follows:
 Patients with premorbid modified Rankin Scale
(mRS) score ≥3.
 Patients for whom a complete NIH Stroke Score
cannot be obtained.
 Hemiplegic migraine with no arterial occlusion on
baseline CT.
 Seizure at stroke onset and no visible occlusion on
baseline CT.
 Intracranial haemorrhage on baseline CT.
 Clinical presentation suggesting subarachnoid
haemorrhage even if baseline CT is normal.
 Large areas of hypodense ischaemic changes on
baseline CT.
 Patients with primary endovascular treatment.
 Patients with systolic blood pressure >180 mm Hg
or diastolic blood pressure >110 mm Hg despite of
blood pressure lowering therapy.
 Pregnant or breast feeding.
 Known bleeding diathesis; use of oral anticoagulants
and INR ≥1.4; heparin <48 hours and increasedAPTT; low molecular weight heparin(oid) <24 hours;
new oral anticoagulants <12 hours; any other
investigational drug <14 days.
 Sepsis, endocarditis.
 Patients with arterial puncture at a noncompressible
site or lumbar puncture <7 days; major surgery or
serious trauma <14 days; gastrointestinal or urinary
tract hemorrhage <14 days; clinical stroke <2 months;
history of intracranial haemorrhage; CNS
neurosurgery <2 months; serious head
trauma <2 months; pericarditis; any serious medical
illness likely to interact with treatment; confounding
pre-existent neurological or psychiatric disease;
unlikely to complete follow-up.Per protocol exclusion after randomisation
The Norwegian Sonothrombolysis in Acute Stroke Study
(NOR-SASS) [20] is a randomised study of Sonothrombo-
lysis vs. sham Sonothrombolysis, superimposed on the
NOR-TEST trial. Patients who receive NOR-TEST treat-
ment (randomisation 1) and thereafter receive NOR-SASS
sonothrombolysis (randomisation 2) are per protocol re-
moved from NOR-TEST. Patients receiving sham sono-
thrombolysis are kept within NOR-TEST.Acute treatment and Stroke Unit care
Patients are treated according to the Departments’
Standard Operating Procedures (SOP) and will receive
(state-of-the-art) multidisciplinary stroke unit care. Sys-
tolic blood pressure >180 mm Hg and/or diastolic blood
pressure >110 mm Hg is treated with iv bolus of labetalol
(Trandate®) 50 mg (10 ml) followed by infusion of labetalol
as appropriate.
Thrombolytic treatment must start <4½ hours after
symptom onset. Alteplase is given in a dose of 0.9 mg/kg
(10% bolus + 90% infusion/1 hour), maximum dose 90 mg.
Tenecteplase is given in a dose of 0.4 mg/kg as bolus,
maximum dose 40 mg.
Endovascular treatment with mechanical embolec-
tomy is initiated within 4½ hours after symptom onset
if an accessible arterial occlusion is identified, or within
6 hours if based on penumbra assessment (as defined
by local treatment protocols). The choice of embolec-
tomy device is left to the experience and competence of
the investigator. The use of conscious sedation or gen-
eral anaesthesia during the endovascular procedure is
registered.
If an anaphylactoid reaction occurs with alteplase or
tenecteplase, treatment will immediately be stopped
and appropriate anaphylactoid treatment given accord-
ing to the Departments SOP. If an intracranial bleeding
is clinically suspected, alteplase will immediately be
stopped (tenecteplase is already given as a bolus) and an
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according to SOP.
Work-up
Neurological deficits are documented with National
Institutes of Health Stroke Scale (NIHSS). Function is
documented with mRS and Barthel Index (BI).
On admission, native CT with CT angiography (CTA)
(or MRI/MRA) is performed. Baseline native CT is
assessed using the Alberta Stroke Program Early CT score
(ASPECTS) [21]. Intracranial MCA occlusions are tricho-
tomized in none, distal (MCA2), or proximal (MCA1) oc-
clusion. Other occlusions are defined as appropriate. MRI/
MRA (or CT/CTA) is repeated after 24–36 hours to verify
and assess infarction, assess intracranial recanalisation and
to detect haemorrhagic transformations. Radiological
assessment is performed by investigators blinded to type
of thrombolysis. Long-term follow-up is performed as
an Outpatient Clinic visit or by telephone interview at
3 months by a blinded and certified stroke nurse.
Patients excluded from NOR-TEST within the thera-
peutic time window of 4½ hours are also to be assessed
clinically, and as far as possible also radiologically, in order
to make an analysis of centre differences in inclusion/
exclusion possible.
Clinical outcome (neurology and function)
Early clinical outcome is defined by NIHSS score at 2 hours
(NIHSS2) and 24–36 hours (NIHSS24) and assessed in an
unblinded fashion by the investigator:
 Major Neurological Improvement: NIHSS = 0 or
reduction of ≥4 NIHSS points compared with
baseline (NIHSS0).
 Absolute reduction in NIHSS: NIHSS =ΔNIHSS0–
NIHSS2 and ΔNIHSS = NIHSS0–NIHSS24.
Short term functional outcome (day 7, or earlier if earl-
ier discharge) is assessed in a blinded fashion by a trained
and certified stroke nurse or neurologist and defined by
mRS score:
 Sliding dichotomy/responder analysis: Excellent
outcome is defined as mRS 0 with baseline NIHSS ≤7,
as mRS 0–1 with baseline NIHSS 8–14, as mRS 0–2
with baseline NIHSS ≥15.
Long term functional outcome (day 90) is defined at
by mRS score:
 Fixed dichotomy: Excellent (mRS 0–1) vs. unfavourable
outcome (mRS 2–6) (primary study endpoint).
 Fixed dichotomy: Good (mRS 0–2) outcome vs. bad
outcome (mRS 3–6). Sliding dichotomy/responder analysis: Excellent
outcome defined as mRS 0 with baseline NIHSS ≤7,
as mRS 0–1 with baseline NIHSS 8–14, as mRS 0–2
with baseline NIHSS ≥15.
 Single mRS group comparison.
Final follow-up at 90 days is performed in a blinded fash-
ion at the Outpatient Clinic or by telephone, by a stroke
nurse certified in NIHSS and mRS assessment (http://nihss-
english.trainingcampus.net/uas/modules/trees/windex.aspx;
http://rankin-english.trainingcampus.net/uas/modules/
trees/windex.aspx).
Vascular outcome (recanalisation)
24-hour recanalisation is assessed by MRA (or CTA
when MRA is not possible) by a neurologist and/or
neuroradiologist blinded to the drug used and detailed
clinical data [22]. Vascular patency is assessed using
adapted Thrombolysis in Myocardial Infarction (TIMI)
criteria [22]. Vessel occlusion status is defined as
complete occlusion (TIMI 0), minimal flow (TIMI 1),
partial flow (TIMI 2), or normal flow (TIMI 3). Major
vessel recanalisation is defined as improvement in
baseline to 24–36 h TIMI score of ≥2, or complete
recanalisation.
Brain imaging outcome (infarct)
24-hour infarct is assessed by 24-hour MR-DWI (or CT
when MRI is not possible) by a neuroradiologist in a clin-
ically blinded fashion. The diagnostic work-up is sum-
marised in Table 1.
Safety outcome (bleedings and death)
Patients are monitored in the stroke unit (or ICU if
standard) with NIHSS scoring at close intervals for 24–
36 hours. Haemorrhagic transformation is assessed by
24-hour MRI (or CT when MRI is not possible) by a
neuroradiologist blinded to all clinical data.
Haemorrhagic transformation (ECASS criteria) is cate-
gorised as:
 Haemorrhagic infarction 1 (HI1) = small petechiae
along the margins of the infarct
 Haemorrhagic infarction 2 (HI2) = confluent
petechiae within the infarcted area but no
space-occupying effect
 Parenchymal haemorrhage (PH1) = blood clots in
30% or less of the infarcted area with some slight
space-occupying effect
 Parenchymal haemorrhage (PH2) = blood clots in
more than 30% of the infarcted area with substantial
space-occupying effect
 Remote parenchymal haemorrhage (rPH) = bleeding
outside the infarcted area
Table 1 Assessment of patients with acute ischaemic stroke admitted <4½ hours
Timepoint → Procedure ↓ Baseline + 2 h (after Rp/) + 24 h (22–36 h) + 48 h (42–54 h) Day 7 or earlier discharge Day 90
NIHSS score X X X X X
CT/CTA/MRI/MRA X X
ECG X
Modified Rankin Scale (mRS) X X
Barthel Index (BI) X
Check Recurrent stroke/TIA X
Check Acute coronary heart disease X
Logallo et al. BMC Neurology 2014, 14:106 Page 5 of 7
http://www.biomedcentral.com/1471-2377/14/106Symptomatic intracranial haemorrhage (SICH) is
assessed as:
 local or remote parenchymal haemorrhage type 2 on
the 24–36 h post-treatment imaging scan, combined
with a neurological deterioration of 4 points or more
on the NIHSS from baseline or from the lowest
NIHSS value between baseline and 24 h, or leading
to death (SITS-MOST criteria).
In order to facilitate comparison with published stud-
ies, SICH is also assessed:
 as any haemorrhage plus any neurological
deterioration [NIHSS score ≥1] or that leads to
death within 7 days (NINDS criteria; Cochrane
criteria)
 blood at any site in the brain on the CT scan,
clinical deterioration or adverse events indicating
clinical worsening (drowsiness, increase of
hemiparesis) or causing a increase in the NIHSS
score of 4 or more points (ECASS II criteria)
 any apparently extravascular blood in the brain or
within the cranium associated with clinical
deterioration (defined by an increase in the NIHSS
score of 4 or more points) or death, and that is
identified as the predominant cause of the
neurological deterioration (ECASS III criteria)
All procedural complications related to intraarterial
embolectomy (groin hematoma, vessel dissection, vessel
perforation, subarachnoid haemorrhage) are registered.
Death within 90 days is registered. Death is checked
against the National Public Register.Study endpoints
The primary study endpoint is favourable functional out-
come defined as mRS 0–1 at 90 days. Secondary study
endpoints are: 1) Haemorrhagic transformation (haem-
orrhagic infarct/haematoma); 2) Symptomatic cerebral
haemorrhage on CT 24–48 hours; 3) Major neurologicalimprovement at 24 hours; 4) Recanalisation at 24–36
hours; 5) death.
Safety monitoring
Safety monitoring is performed by an independent Data
safety and monitoring committee (DSMC).
Intravenous thrombolysis: Periodic safety review is
performed after each 40 enrolled patients (20 per group).
Formal interim analysis is performed once a year. For-
mal safety “stopping rules” are applied for safety. Based
on data from the literature on the frequency of SICH in
trials or clinical series of thrombolysis, the overall stop-
ping rule is set at a rate of SICH that exceeds 8% in any
group, the stopping rule for tenecteplase 0.4 mg/kg is
set at a 2% excess of SICH. In the event of SICH sur-
passing these limits, the trial will temporarily (pending
review of the data) stop further patient accrual. To
maintain blinding within the committee, the calculations
will be performed by a statistical consultant, who is re-
quired to simply report whether the “stopping rule” is
met (i.e., no disclosure of interim data if the stopping
guideline is not met). If the DSMC finds unacceptable
safety (bleedings/death) with tenecteplase, the tier 0.4 mg/
kg will be stopped and the trial continued with a step-
down to tenecteplase 0.25 mg/kg.
Intra-arterial embolectomy: Periodic safety review is
performed after each 30 enrolled patients (15 per group).
Based on data from the literature on the frequency of
SICH in trials or clinical series of endovascular embolec-
tomy, the overall stopping rule is set at a rate of SICH
that exceeds 14% (2/15) in any group. In the event of
SICH surpassing these limits, the trial will temporarily
(pending review of the data) stop accrual of patients
treated with endovascular embolectomy.
All suspected unexpected serious adverse reactions,
which may be related to the study drug, will be reported
to the Norwegian Medicines Agency and to the DSMC.
All serious adverse events, i.e. bleedings and deaths, and
other Adverse Events will be reported to the DSMC.
The overall rate of bleeding complications will be com-
pared with historical data from NORSTROKE 2007–2011,
the pooled analysis of IV alteplase trials [17], SITS-MOST
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tients above 80 years of age [24]. The mortality rate at
7 days will be compared with historical data from NOR-
STROKE 2007–2011.
The over-all rate of bleeding complications will be com-
pared with historical data from NORSTROKE 2007–2012
and from Stavanger University Hospital [25], Interven-
tional Management of Stroke (IMS) I [26], IMS II [27] and
IMS III [28].
Safety outcome (futility)
If the trial shows no significant difference between the
two treatment groups, the DSMC may stop the trial, if
there also is a clear trend towards increased bleeding
rate in one group.
Statistical analysis
The primary analysis in NOR-TEST is to test whether
tenecteplase is superior to alteplase. The primary analysis
is an “intention to treat” analysis. The results will also
be tested in a “per protocol” analysis. The data from the
Wake-up-subset and Embolectomy-subset will be analysed
separately and not as a part of the main NOR-TEST data
set. Excluded patients admitted <4½ hours will also be
analysed for comparison with thrombolysed patients
and for inter-centre inclusion/exclusion differences (bias).
Stratification according to age (≤80 vs. >80), baseline
NIHSS (≤14 vs. >14) and time (0–3 h vs. 3-4½ h) will be
performed.
Ethics & data anonymity
The trial is performed in accordance with the European
‘Guidelines on Good Clinical Research Practice’ (Consol-
idated guideline, CPMP/ICH/135/95) and the Norwegian
‘Forskrift om klinisk utprøving av legemidler til men-
neske’ (FOR 2009-30-10).
NOR-TEST is reviewed and approved by the Regional
Committee for Medical and Health Research Ethics (2011/
2435), and The Norwegian Medicines Agency (12/01402).
NOR-TEST is registered with EudraCT No 2011-005793-
33 and in ClinicalTrials.gov (NCT01949948).
Discussion
Despite indications of clinical superiority of tenecteplase
compared to alteplase [1,9,12], tenecteplase in acute is-
chemic stroke has been studied only in small series with
highly selected patients (visible clot, perfusion mismatch
etc.) [9-11,29]. A large randomised controlled phase 3
trial has not been performed.
NOR-TEST is a pragmatic multi-centre phase 3 trial
with logistic equivalent to the routine chain of treat-
ment. NOR-TEST is therefore easily adopted by all hos-
pitals, securing a high centre compliance and adherence
to the protocol. All patients found eligible for standardalteplase treatment may be included. NOR-TEST will
therefore apply tenecteplase to a general population of
ischaemic stroke patients.
In patients receiving embolectomy, the hypothesised
higher recanalisation rates of tenecteplase as compared
to alteplase may benefit patients, as clots may partially or
completely recanalise prior to the endovascular procedure.
There is no strong evidence that the highest dose of
tenecteplase (0.4 mg/kg) increases the risk of haemor-
rhagic transformation [7,9,13]. In order to maximise the
thrombolytic effect, NOR-TEST therefore is designed
with a high tenecteplase dose together with careful safety
monitoring of major bleedings.
A positive NOR-TEST result may give an impetus to
implementing thrombolysis at a higher rate than today,
and establish a more effective and less harmful treatment
for all ischaemic stroke patients eligible for thrombolysis.Additional file
Additional file 1: Power calculations for excellent outcome (mRS 0-1)
90 days.
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